drugset / Trial / NCT03955042
Pemetrexed for the Treatment of Chordoma
Phase 1
Completed
15 enrolled
Saint John's Cancer Institute
Chordoma Foundation · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: * find out side effects (good and bad) of pemetrexed; * learn more about how pemetrexed might affect the growth of cancer cells; * evaluate tumor characteristics by collecting tumor tissue samples if available; * look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug) in blood and cerebrospinal fluid if available.
Timeline
- Start
- 2019-09-06
- Primary completion
- 2022-07-27
- Completion
- 2023-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 900 mg/m2 | Intravenous |